These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cystic Fibrosis-Related Diabetes: Pathophysiology and Therapeutic Challenges. Kelsey R; Manderson Koivula FN; McClenaghan NH; Kelly C Clin Med Insights Endocrinol Diabetes; 2019; 12():1179551419851770. PubMed ID: 31191067 [TBL] [Abstract][Full Text] [Related]
3. Management of endocrine disease: Cystic fibrosis-related diabetes: novel pathogenic insights opening new therapeutic avenues. Barrio R Eur J Endocrinol; 2015 Apr; 172(4):R131-41. PubMed ID: 25336504 [TBL] [Abstract][Full Text] [Related]
4. The Potential Causes of Cystic Fibrosis-Related Diabetes. Coderre L; Debieche L; Plourde J; Rabasa-Lhoret R; Lesage S Front Endocrinol (Lausanne); 2021; 12():702823. PubMed ID: 34394004 [TBL] [Abstract][Full Text] [Related]
5. Islet-intrinsic effects of CFTR mutation. Koivula FNM; McClenaghan NH; Harper AGS; Kelly C Diabetologia; 2016 Jul; 59(7):1350-1355. PubMed ID: 27033560 [TBL] [Abstract][Full Text] [Related]
6. New Concepts in the Pathogenesis of Cystic Fibrosis-Related Diabetes. Moheet A; Moran A J Clin Endocrinol Metab; 2022 May; 107(6):1503-1509. PubMed ID: 35106591 [TBL] [Abstract][Full Text] [Related]
7. Pancreas and islet morphology in cystic fibrosis: clues to the etiology of cystic fibrosis-related diabetes. Malik SS; Padmanabhan D; Hull-Meichle RL Front Endocrinol (Lausanne); 2023; 14():1269139. PubMed ID: 38075070 [TBL] [Abstract][Full Text] [Related]
14. Understanding the Pancreatic Islet Microenvironment in Cystic Fibrosis and the Extrinsic Pathways Leading to Cystic Fibrosis Related Diabetes. Al-Selwi Y; Shaw JA; Kattner N Clin Med Insights Endocrinol Diabetes; 2021; 14():11795514211048813. PubMed ID: 34675737 [TBL] [Abstract][Full Text] [Related]
15. Cystic fibrosis-related diabetes is caused by islet loss and inflammation. Hart NJ; Aramandla R; Poffenberger G; Fayolle C; Thames AH; Bautista A; Spigelman AF; Babon JAB; DeNicola ME; Dadi PK; Bush WS; Balamurugan AN; Brissova M; Dai C; Prasad N; Bottino R; Jacobson DA; Drumm ML; Kent SC; MacDonald PE; Powers AC JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669939 [TBL] [Abstract][Full Text] [Related]
16. MARKEDLY DELAYED INSULIN SECRETION AND A HIGH RATE OF UNDETECTED OVERT DIABETES CHARACTERIZE GLUCOSE METABOLISM IN ADULT PATIENTS WITH CYSTIC FIBROSIS AFTER LUNG TRANSPLANTATION. Winhofer Y; Wolf P; Fellinger P; Tura A; Hillebrand P; Staufer K; Trauner M; Jaksch P; Muraközy G; Kautzky-Willer A; Pacini G; Krebs M; Luger A; Kazemi-Shirazi L Endocr Pract; 2019 Mar; 25(3):254-262. PubMed ID: 30913015 [TBL] [Abstract][Full Text] [Related]
17. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. Kutney K; Donnola SB; Flask CA; Gubitosi-Klug R; O'Riordan M; McBennett K; Sferra TJ; Kaminski B World J Hepatol; 2019 Dec; 11(12):761-772. PubMed ID: 31966908 [TBL] [Abstract][Full Text] [Related]
18. The course of glucose intolerance in children with cystic fibrosis: a retrospective study - preliminary report. Piechowiak K; Trippenbach-Dulska H; Walicka-Serzysko K Dev Period Med; 2015; 19(1):80-91. PubMed ID: 26003073 [TBL] [Abstract][Full Text] [Related]
19. The role of genetic modifiers, inflammation and CFTR in the pathogenesis of Cystic fibrosis related diabetes. Hasan S; Soltman S; Wood C; Blackman SM J Clin Transl Endocrinol; 2022 Mar; 27():100287. PubMed ID: 34976741 [TBL] [Abstract][Full Text] [Related]
20. CFTR silencing in pancreatic β-cells reveals a functional impact on glucose-stimulated insulin secretion and oxidative stress response. Ntimbane T; Mailhot G; Spahis S; Rabasa-Lhoret R; Kleme ML; Melloul D; Brochiero E; Berthiaume Y; Levy E Am J Physiol Endocrinol Metab; 2016 Feb; 310(3):E200-12. PubMed ID: 26625901 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]